Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Oestrogen receptor-a (ERa)-regulated transcription in breast cancer cells involves protein co-factors that contribute to the regulation of chromatin structure. How do these relate with ER activity and potentially with the activity of breast cancer drugs, including tamoxifen?
Advances in antibody engineering make it possible to produce various recombinant proteins that exploit the specificity of the antibody- combining site to manipulate tumour-related signalling, and to stimulate anti-tumour immune responses. but can we improve antibodies further to fully engage the tumour immune response?
Breast cancer is not a single disease, but is instead a collection of diseases that have distinct histopathological features, genetic and genomic variability, and diverse prognostic outcomes. What is the most powerful way to investigate this heterogeneous disease?
The myeloproliferative disorders (MPD) polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors, and most patients with these diseases acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). What are the implications of these findings for MPD?
This Perspective discusses the feasibility of identifying oncoantigens (proteins required for tumour progression) using mouse models and human mRNA profiling data. Will such oncoantigens make good cancer vaccine targets?
